Owner Elixir Pharmaceuticals, Inc. a Delaware corporation

Service Watermark

Various Convention priority claimed: 16 April 2004, United States of America, No. 78/403395 in respect of NUTRACEUTICAL PREPARATIONS FOR USE IN THE PREVENTION AND/OR TREATMENT OF HUMAN GENETIC AND AGE RELATED DISORDERS, FOR USE IN SLOWING DOWN THE AGING PROCESS A

Class 5 Nutraceutical preparations including nutraceutical preparations for use in the prevention and/or treatment of human genetic and age-related disorders, for use in slowing down the aging process and extending life span, and for use in reducing occurrence of cancer, cardiovascular disease, degenerative and cognitive diseases, arthritis, diabetes, obesity, and pathogenic infections and complications of diabetes and obesity; nutraceutical preparations for use in the prevention and/or treatment of human genetic and age-related disorders, for use in slowing down the aging process and extending life span, and for use in reducing occurrence of cancer, cardiovascular disease, degenerative and cognitive diseases, arthritis, diabetes, obesity, and pathogenic infections and complications of diabetes and obesity comparable with the reduction seen in human centenarians

Class 42 Research and development in the field of nutraceuticals for human genetics, genomics, aging and life span extension, and reduction and elimination of diseases of aging; nutraceutical research and development in the field of nutraceuticals, using centenarians for human genetics, genomics, aging and life span extension, and reduction and elimination of diseases of aging